Cartesian Therapeutics, Inc. Common Stock
RNACCartesian Therapeutics, Inc. (RNAC) focuses on developing cell-based immunotherapies to treat various diseases. The company leverages its proprietary platform to engineer natural killer (NK) cells and other immune cells for targeted therapeutic applications, aiming to provide precise and effective treatments with minimal side effects.
Company News
The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence...
Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market inclu...
AstraZeneca reported positive Phase 3 trial results for gefurulimab, a drug candidate treating generalized myasthenia gravis, demonstrating significant improvement in patient symptoms with no new safety concerns.
Cartesian Therapeutics reported positive long-term results from its Phase 2b trial of Descartes-08 in myasthenia gravis, with plans to initiate a Phase 3 trial in Q2 2025. The company also expects to report preliminary data from a Phase 2 trial of Descartes-08 in systemic lupus erythematosus and initiate a Phase 2 pediatric basket trial in H2 202...
US stock futures were volatile ahead of the market open, with experts advising investors to focus on capital preservation due to high uncertainty. The article discusses concerns over liquidity issues in the US banking system and the impact of tariffs on the markets.
